Table II.

Prognostic factors for progression-free survival and overall survival.

First author/s, year	Progression/event-free survival	Overall survival	(Refs.)
Present study	Female, age ≤60 years, stage I–II disease, with radiotherapy, CR achievement	Female, age ≤60 years, IPI ≤1, high-intensity chemotherapy, with radiotherapy, CR achievement	-
Savage et al, 2006	-	ECOG ≤1	(8)
Todeschini et al, 2004	CR achievement, V/MACOP-B chemotherapy	CR achievement, V/MACOP-B chemotherapy	(9)
Yang et al, 2015	-	Rituximab induction, age ≤60 years	(10)
Aoki et al, 2014	Without pleural or pericardial effusion, IPI <3	Without pleural or pericardial effusion, IPI <3	(11)
Zhou et al, 2020	IPI ≤1, stage I–II disease, Ki-67 expression <70%, higher lymphocyte/monocyte ratios, MUM1 expression	IPI ≤1, Ki-67 expression <70%, age ≤60 years, maximum standardized uptake values of positron emission tomography imaging ≤11.6, higher lymphocyte/monocyte ratios, MUM1 expression	(12)

IPI, International Prognostic Index; CR, complete response; ECOG, Eastern Cooperative Oncology Group; V/MACOP-B, etoposide/methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisolone and bleomycin; MUM1, multiple myeloma 1.